{"id":40087,"date":"2017-08-08T06:34:03","date_gmt":"2017-08-08T10:34:03","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40087"},"modified":"2017-08-08T02:36:56","modified_gmt":"2017-08-08T06:36:56","slug":"celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087","title":{"rendered":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients"},"content":{"rendered":"<p>Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company\u2019s 1L-12 gene-mediated immunotherapy, together with standard care for treatment of the lately-diagnosed patients of Stage 3 and 4 ovarian cancer. The patients went through the neoadjuvant chemotherapy (NACT) and afterwards take the interval debulking surgery.<\/p>\n<p>The translational research data was analyzed with the leading immune-oncology specialists from Roswell Park Cancer Institute. The key translational data from the first 12 of the 15 participants were summarized as follows:<\/p>\n<ul>\n<li>The changes in the stimulated immune cytokines, pro-tumor VEGF, and IFN- \u03b3 levels. The tracked immunological changes were consistent and were in line with the IL-12 based mechanism.<\/li>\n<li>The effects examined in IHC analysis were reported to be decreasing in the mass of the immunosuppressive T-cell signals including the FoxP3, PD-1, PDL-1, and IDO-1) ns an increase in the CD8+cells in the tumor<\/li>\n<li>The CD8+ cells to immunosuppressive ratio increased gradually by 75% in patients proposing an entire shift in tumor surroundings following the treatment with GEN-1. The increase in CD8+ cells is an indication and a great predictor of an overall improvement.<\/li>\n<\/ul>\n<p>The findings shows that GEN-1 is biologically active in the ovarian cancer patients and can develop a dramatic change in the tumor microenvironment by promoting the pro-immune T-cell population.<\/p>\n<p>According to Dr. Khursheed Anwer, the executive vice president and chief science officer at Celsion, the diverse immunological shift in the confined tumor environment is a clinical indication that warrants continuous development of GEN-1 and IL-12 immunotherapy as a possible adjuvant in the first and second phases of ovarian cancer.<\/p>\n<p>In addition, the pro-immune changes in the cancer disease microenvironment also support the findings when GEN-1 is combined with other interesting immune-oncology therapies such as the adaptive T-cell and other check-point inhibitors.<\/p>\n<p>Celsion had previously announced updates of the research findings from its OVARIAN study presented to the American Society of Clinical Oncology in June.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company\u2019s [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":40096,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12821,2370,2371],"stock_ticker":[],"class_list":["post-40087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-celsion-corporation","tag-celsion-corporation-nasdaqclsn","tag-nasdaqclsn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company\u2019s [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-08T10:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients\",\"datePublished\":\"2017-08-08T10:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg\",\"keywords\":[\"Celsion Corporation\",\"Celsion Corporation (NASDAQ:CLSN)\",\"NASDAQ:CLSN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\",\"name\":\"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg\",\"datePublished\":\"2017-08-08T10:34:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087","og_locale":"en_US","og_type":"article","og_title":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR","og_description":"Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company\u2019s [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-08-08T10:34:03+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients","datePublished":"2017-08-08T10:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg","keywords":["Celsion Corporation","Celsion Corporation (NASDAQ:CLSN)","NASDAQ:CLSN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087","url":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087","name":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg","datePublished":"2017-08-08T10:34:03+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40095-maxresdefault__1_.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celsion-corporation-nasdaqclsn-announces-translational-data-from-ovation-study-in-latest-diagnosed-advanced-ovarian-cancer-patients-40087#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40087"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40087\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40096"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40087"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}